Benefit of heart rate reduction in heart failure.
作者信息
Hasenfuss Gerd
机构信息
Department of Cardiology and Pneumology, University Medical Center, Heart Research Center Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany.
出版信息
Curr Heart Fail Rep. 2010 Dec;7(4):156-8. doi: 10.1007/s11897-010-0029-1.
Abstract
摘要
相似文献
1
Benefit of heart rate reduction in heart failure.心力衰竭时心率降低的益处。
Curr Heart Fail Rep. 2010 Dec;7(4):156-8. doi: 10.1007/s11897-010-0029-1.
2
Ivabradine and outcomes in chronic heart failure.伊伐布雷定与慢性心力衰竭的预后
Lancet. 2010 Dec 18;376(9758):2069; author reply 2069-70. doi: 10.1016/S0140-6736(10)62286-6.
3
Ivabradine and outcomes in chronic heart failure.伊伐布雷定与慢性心力衰竭的预后
Lancet. 2010 Dec 18;376(9758):2069; author reply 2069-70. doi: 10.1016/S0140-6736(10)62285-4.
4
The Use and Indication of Ivabradine in Heart Failure.伊伐布雷定在心力衰竭中的应用和适应证。
Heart Fail Clin. 2018 Oct;14(4):493-500. doi: 10.1016/j.hfc.2018.06.001. Epub 2018 Aug 18.
5
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.心率作为慢性心力衰竭的危险因素（SHIFT）：一项随机安慰剂对照试验中心率与结局的关系。
Lancet. 2010 Sep 11;376(9744):886-94. doi: 10.1016/S0140-6736(10)61259-7.
6
[Management of heart failure: a challenge for healthcare systems].[心力衰竭的管理：医疗系统面临的一项挑战]
Bull Acad Natl Med. 2012 Jun;196(6):1159-65; discussion 1165-7.
7
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.依伐布雷定治疗慢性心力衰竭的疗效评价（SHIFT）：一项随机、安慰剂对照研究
Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1.
8
Ivabradine in Management of Heart Failure: a Critical Appraisal.伊伐布雷定在心力衰竭管理中的应用：一项批判性评估。
Curr Heart Fail Rep. 2016 Feb;13(1):60-9. doi: 10.1007/s11897-016-0276-x.
9
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.关于2016年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南的评论
Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1119-1125. doi: 10.1016/j.rec.2016.10.015.
10
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.依伐布雷定降低慢性心力衰竭患者心率对肾功能的影响：SHIFT 研究分析。
Eur J Heart Fail. 2014 Apr;16(4):426-34. doi: 10.1002/ejhf.59.
引用本文的文献
1
Heart Rate Reduction and Outcomes in Heart Failure Outpatients.心力衰竭门诊患者的心率降低与预后
J Clin Med. 2023 Oct 26;12(21):6779. doi: 10.3390/jcm12216779.
2
Resting heart rate predicts all-cause mortality in sub-Saharan African patients with heart failure: a prospective analysis from the Douala Heart failure registry (Do-HF).静息心率可预测撒哈拉以南非洲心力衰竭患者的全因死亡率：来自杜阿拉心力衰竭登记处（Do-HF）的前瞻性分析。
Cardiovasc Diagn Ther. 2021 Feb;11(1):111-119. doi: 10.21037/cdt-20-785.
3
Heart rate and blood pressure monitoring in heart failure.心力衰竭中的心率和血压监测
Eur Heart J Suppl. 2019 Dec;21(Suppl M):M13-M16. doi: 10.1093/eurheartj/suz217. Epub 2019 Dec 31.
4
Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.伊伐布雷定：心血管疾病及其他新适应症的证据与当前作用
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20.
5
The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis.ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后无复流现象的预测因素：一项荟萃分析。
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S406-S418. doi: 10.1016/j.ihj.2018.01.032. Epub 2018 Jan 31.
本文引用的文献
1
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.依伐布雷定治疗慢性心力衰竭的疗效评价（SHIFT）：一项随机、安慰剂对照研究
Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1.
2
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.心率作为冠心病合并左心室收缩功能不全患者的预后风险因素（BEAUTIFUL研究）：一项随机对照试验的亚组分析
Lancet. 2008 Sep 6;372(9641):817-21. doi: 10.1016/S0140-6736(08)61171-X. Epub 2008 Aug 29.
3
High heart rate: a cardiovascular risk factor?高心率：一种心血管危险因素？
Eur Heart J. 2006 Oct;27(20):2387-93. doi: 10.1093/eurheartj/ehl259. Epub 2006 Sep 25.
4
Calcium cycling in congestive heart failure.充血性心力衰竭中的钙循环
J Mol Cell Cardiol. 2002 Aug;34(8):951-69. doi: 10.1006/jmcc.2002.2037.
5
Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I.
Eur Heart J. 1999 Jan;20(2):136-9. doi: 10.1053/euhj.1998.1098.
6
Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy.力-频率关系对非衰竭心脏患者和扩张型心肌病患者血流动力学及左心室功能的影响。
Eur Heart J. 1994 Feb;15(2):164-70. doi: 10.1093/oxfordjournals.eurheartj.a060471.
7
Heart rate reduction--a mechanism of benefit?心率降低——一种获益机制？
Eur Heart J. 1987 Dec;8 Suppl L:115-22. doi: 10.1093/eurheartj/8.suppl_l.115.
8
Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone.扩张型心肌病患者的心肌能量代谢。硝普钠和依诺昔酮的影响。
Circulation. 1989 Jul;80(1):51-64. doi: 10.1161/01.cir.80.1.51.
9
Altered myocardial force-frequency relation in human heart failure.人类心力衰竭时心肌力-频率关系的改变
Circulation. 1992 May;85(5):1743-50. doi: 10.1161/01.cir.85.5.1743.
Zotero 插件